FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
In a tour a the second (In)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOGER JOSHUA S							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								tionship o all applic Directo	,			
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 11/26/2008								X	Officer (give title below) President & CEO				pecify
130 WAVERLY STREET (Street) CAMBRIDGE MA 02139						4. If Amendment, Date of Original Filed (Month/Day/Year)									ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)																
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/					ction	n 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 11/26/20)8		M		13,000	A	\$13.6	63 1,10		8,044		D		
Common Stock 11/26/20)8		S ⁽¹⁾		13,000	D	\$24.33	(2)(3) 1,095		5,044		D		
Common Stock															12	,445		I 4	401(k)
Common Stock														207,500		7,500			Shares in trust ⁽⁴⁾
			Table II								posed of, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/		Code (I				6. Date Exerc Expiration D (Month/Day/\)		ate	of Secur Underlyi	ng e Security	De Se	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amoun or Numbe of Shares	r					
Stock	\$13.63	11/26/2008	I		M		ı	13,000	(5	5)	12/09/2008	Common	13.00	o I	\$ <mark>0</mark>	12,000		D	1

Explanation of Responses:

- 1. Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$24.33 (range \$24.05 to \$24.69).
- 3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.
- 5. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-

12/01/2008

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.